Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on July 10, 2025, the Compensation Committee of the Board ...

Swedish biotech Camurus (Nasdaq Stockholm: CAMX) has secured EU marketing authorization for its once-monthly acromegaly ...

Camurus (NASDAQ STO: CAMX) today announced that the European Commission (EC) has granted Oczyesa®, octreotide subcutaneous depot, marketing authorization* for the maintenance treatment in adult ...

Oczyesa® (CAM2029) is a ready-to-use, long-acting subcutaneous depot of octreotide indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated ...

Acromegaly is a rare, progressive disease, typically caused by a tumor of the pituitary gland producing excess growth hormone and stimulating increased insulin growth factor-1 (IGF-1) levels.

Long-term efficacy and safety data on PALSONIFYTM (paltusotine) in acromegaly to be presented, including evidence of both ...

Camurus’ Oczyesa receives European marketing authorization for treatment of acromegaly: Lund, Sweden Wednesday, July 2, 2025, 17:00 Hrs [IST] Camurus, an international, science- ...

Andre the Giant, a wrestling icon from the Rock n Wrestling Era, tragically passed away at the age of 46 due to a heart attack in Paris. His death was ...

China has about 20 million patients with rare diseases, with more than 200,000 new cases each year. The first batch of treatment guidelines was published in 2019 and covered 121 rare diseases.